- Home
- TONX vs UNCY Comparison
TONX vs UNCY Comparison
Compare TONX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TONX | UNCY |
|---|---|---|
| Price | $3.34 | $6.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 301.3K | ★ 901.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $3.72 |
| 52 Week High | $8.23 | $8.74 |
Technical Indicators
Market Signals| Indicator | TONX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 42.30 |
| Support Level | $2.95 | $6.77 |
| Resistance Level | $3.47 | $7.34 |
| Average True Range (ATR) | 0.36 | 0.56 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 29.68 | 13.80 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.